ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...

Backed by Novartis and Orbimed, Adicet joins immunotherapy crowd with $51M round

John Carroll Adicet Bio has jumped out of stealth mode–more or less–with a $ 51 million A round and plans to combine two platform technologies into a next-gen approach ...

Novartis divvies up troubled Alcon; targets $1B in cuts in R&D and manufacturing rejig

Tracy Staton Novartis has a problem with its eye-care unit Alcon: It's not performing. As expected, the division dragged down the Swiss drugmaker's fourth-quarter and full-year ...

Novartis reshuffles its $9B R&D operation to save $1B a year

Damian Garde Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines. FierceBiotech News

Novartis adds 100 jobs at Lek site in Slovenia as it muscles up on biosimilars

Eric Palmer Novartis was the first drugmaker to get a biosimilar approved in the U.S. and has set itself up to be a major player in the growth of the biologic copies. That is going ...

BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton Predicting the future–particularly when it comes to Big Pharma's prospects for growth and earnings–is a favorite pastime among industry-watchers. Even better ...

Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Carly Helfand Novartis has been working hard to rack up indications for new med Cosentyx before other next-gen psoriasis competitors hit the scene. And now, it's accomplished that ...

Cardiorentis bags $60M as PhIII nears end; J&J backs HIV player; Novartis nears Horsham sale

Nick Paul Taylor Our top stories in this week's EuroBiotech Report involve the transfer of more than $ 100 million (€92 million) from the wallets of investors to the bank ...

Local council moves to buy Novartis’ Horsham site with view to creating science park

Nick Paul Taylor Novartis is on the verge of offloading its former R&D site in Horsham, U.K., to the local council. The agreement of initial terms with West Sussex council ...

Novartis, not to be outdone by respiratory rivals, inks ‘smart inhaler’ deal

Carly Helfand Respiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis wants a part ...

Novartis provides $170M to kick off Surface Oncology partnership

John Carroll Fledgling Cambridge, MA-based startup Surface Oncology has pulled off its first Big Pharma deal, grabbing $ 170 million in near-term milestones, an upfront and research ...
Page 1 of 1412345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS